HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Aurobindo Pharma inks pact to acquire balance 49% stake in GLS Pharma
Sep-18-2024

Aurobindo Pharma has entered into a binding agreement on September 18, 2024, with GLS Pharma, a subsidiary of the Company and its promoters for acquisition of balance 5,90,361 equity shares of Rs 10 each (49% of GLS Pharma) for a purchase consideration of Rs 22.5 crore. The shares are being acquired at a price of Rs 381.12 per share. GLS will become a wholly owned subsidiary of the Company post the acquisition. The completion of the acquisition is estimated before December 31, 2024. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>